Galiximab is a monoclonal antibody designed for the treatment of B-cell lymphoma. As of September 2009[update], it is undergoing Phase III clinical trials.[1] The drug is a chimeric antibody from Macaca irus and Homo sapiens.[2]
References[edit]
External links[edit]
|
|
|
Intracellular
(initiation) |
|
|
Intracellular
(reception) |
|
|
| Extracellular |
|
|
|
|
| Immune system ("-l(i[m])-") |
| Human ("-limu-") |
|
|
| Mouse ("-limo-") |
|
|
| Chimeric ("-lixi-") |
|
|
| Humanized ("-lizu-") |
|
|
Chimeric + humanized
("-lixizu-") |
|
|
|
| Interleukin ("-k(i[n])-") |
| Human ("-kinu-") |
|
|
| Humanized ("-kizu-", "-kinzu-") |
|
|
|
| Inflammatory lesions ("-les-") |
|
|
|
|
